Earnings summaries and quarterly performance for Vera Therapeutics.
Executive leadership at Vera Therapeutics.
Board of directors at Vera Therapeutics.
Research analysts covering Vera Therapeutics.
Recent press releases and 8-K filings for VERA.
Vera Therapeutics Files BLA for Atacicept Following Positive Phase 3 Results
VERA
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Vera Therapeutics, a San Francisco-based biotechnology company, has filed a Biologics License Application (BLA) for atacicept following positive Phase 3 results for IgA nephropathy (IgAN), with a PDUFA target action date of July 7, 2026.
- Atacicept, a dual BAFF/APRIL inhibitor, demonstrated significant efficacy in the ORIGIN 3 interim analysis, showing a 42% mean UPCR reduction at Week 36 compared to placebo, along with 68% Gd-IgA1 reduction and 81% hematuria resolution.
- The drug also exhibits a differentiated safety profile with no serious infections or clinically relevant hypogammaglobulinemia, and offers desirable patient-centric features like at-home, weekly administration.
- Vera Therapeutics projects a US launch for atacicept in 2027 and full approval in 2028, targeting a potential $10B+ market opportunity in pipeline autoimmune diseases.
Jan 28, 2026, 12:00 PM
Vera Therapeutics Provides Atacicept Commercial Launch Outlook and Regulatory Update
VERA
Product Launch
Guidance Update
- Vera Therapeutics' lead product candidate, atacicept, received priority review from the U.S. FDA with a PDUFA date of July 7, 2026, and is on track for commercialization in IgAN this July.
- The pivotal phase III trial for atacicept met its primary endpoint, demonstrating a 42% placebo-adjusted reduction in proteinuria at 36 weeks, with a safety profile similar to placebo.
- The company reported a strong cash position of $779 million (pro forma) and access to $425 million in non-dilutive capital as of January 13, 2026.
- Vera is preparing for the U.S. commercial launch with a planned sales force of 82 representatives to target the estimated 160,000 diagnosed IgAN patients in the U.S..
- Two-year confirmatory GFR results from the ongoing phase III trial are expected in early 2027, with full approval projected for 2028.
Jan 13, 2026, 10:15 PM
Vera Therapeutics Provides 2026 Outlook, Highlights Atacicept PDUFA Date and Commercial Launch Plans
VERA
Product Launch
Guidance Update
- Vera Therapeutics is preparing for the commercial launch of its lead product candidate, atacicept, for IgA nephropathy (IgAN), with a U.S. FDA PDUFA date of July 7, 2026, following priority review.
- The company reported a strong financial position with $779 million in pro forma cash and access to $425 million in non-dilutive capital.
- The pivotal phase III trial for atacicept met its primary endpoint, demonstrating a 42% placebo-adjusted delta reduction in proteinuria at 36 weeks.
- Vera plans to hire 82 sales representatives for the U.S. launch to target over half of the 11,000 nephrologists in the country.
- Intellectual property for atacicept's methods of use extends to 2041, with a goal to reach 2047 and beyond.
Jan 13, 2026, 10:15 PM
Vera Therapeutics Provides 2026 Outlook and Atacicept Commercialization Update
VERA
Product Launch
Guidance Update
New Projects/Investments
- Vera Therapeutics' lead product candidate, atacicept, a dual BAFF/APRIL inhibitor for IgA nephropathy (IgAN), received priority review from the U.S. FDA with a PDUFA date of July 7, 2026, and is on track for commercialization in IgAN in July 2026.
- The pivotal phase III trial for atacicept met its primary endpoint, demonstrating a 42% placebo-adjusted reduction in proteinuria at 36 weeks, with a clinical safety profile similar to placebo.
- The company reported a strong pro forma cash position of $779 million and access to $425 million in non-dilutive capital.
- Vera estimates the U.S. market for diagnosed IgAN patients at approximately 160,000 and is hiring 82 sales representatives for the upcoming launch.
- Vera is also developing a monthly formulation of atacicept, with data from an ongoing dose range finding study expected around mid-2026.
Jan 13, 2026, 10:15 PM
Vera Therapeutics' Atacicept BLA Granted Priority Review by FDA
VERA
Product Launch
New Projects/Investments
- Vera Therapeutics announced that its Biologics License Application (BLA) for atacicept for the treatment of adults with immunoglobulin A nephropathy (IgAN) was accepted for Priority Review by the U.S. Food and Drug Administration (FDA).
- The FDA has assigned a PDUFA target action date of July 7, 2026.
- If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN and is designed for once-weekly, at-home self-administration.
- The BLA submission is supported by data from the ORIGIN 3 trial, which demonstrated a 46% reduction from baseline in proteinuria and a 42% reduction in UPCR compared to placebo at week 36.
Jan 7, 2026, 12:30 PM
Vera Therapeutics Announces Public Offering of Class A Common Stock
VERA
- Vera Therapeutics, Inc. entered into an underwriting agreement on December 9, 2025, for a public offering of 6,138,108 shares of its Class A common stock.
- The shares were offered to the public at a price of $42.50 per share.
- The offering is expected to generate approximately $260.9 million in gross proceeds for the company, before deducting underwriting discounts and commissions and estimated offering expenses.
- The underwriters fully exercised their option on December 10, 2025, to purchase an additional 920,716 shares.
- The closing of the offering is anticipated on December 11, 2025.
Dec 10, 2025, 10:18 PM
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
VERA
- Vera Therapeutics, a late clinical-stage biotechnology company, announced plans to commence a public offering to issue and sell $200.0 million of shares of its Class A common stock.
- The company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of Class A common stock sold in the public offering.
- There is no assurance as to whether or when the proposed offering may be completed or as to its actual size or terms, as it is subject to market and other conditions.
- J.P. Morgan, Goldman Sachs & Co. LLC, Evercore ISI, and Cantor are acting as joint book-running managers for the proposed offering.
Dec 8, 2025, 9:01 PM
Vera Therapeutics Provides Update on Atakicept Phase III Data, BLA Filing, and Commercial Readiness
VERA
Product Launch
New Projects/Investments
Guidance Update
- Vera Therapeutics (VERA) announced positive and compelling Phase III data for its lead product candidate, Atakicept, in IgAN nephropathy, with the BLA filing submitted on November 7 and a potential PDUFA date in July. Atakicept has breakthrough designation.
- The company is well-resourced for the upcoming launch, ending the year with $400 million-$500 million and access to an additional $500 million through a facility with Oxford, providing approximately $1 billion for the first launch year.
- Atakicept is positioned as a differentiated therapy, being the first dual BAF-APRL inhibitor and the only program approaching launch with an autoinjector for patient convenience. Its safety profile is similar to placebo.
- Vera is also advancing its pipeline, including a monthly dosing study for Atakicept with early data expected in 2026, and the acquired VT109, a new molecule with potential for quarterly dosing, with an IND filing as the next catalyst.
Dec 3, 2025, 9:00 PM
Vera Provides Update on Atakicept Regulatory Filing and Launch Preparations
VERA
Product Launch
New Projects/Investments
Guidance Update
- Vera's lead product candidate, Atakicept, for IgA nephropathy (iGAN), has shown positive Phase 3 data, and a Biologics License Application (BLA) was filed on November 7.
- The company expects to hear about a PDUFA date announcement in early January, with a potential PDUFA date in July.
- Atakicept is anticipated to launch with an autoinjector and is positioned as the first dual BAF-APRL inhibitor in the iGAN market, which has an estimated 160,000 biopsy-confirmed cases in the United States.
- Vera is well-capitalized for the upcoming launch, ending the year (FY 2025) with $400 million-$500 million and access to an additional $500 million through a facility, providing roughly $1 billion for the first launch year.
Dec 3, 2025, 9:00 PM
Vera Therapeutics Submits BLA for Atakicept in IgA Nephropathy and Prepares for Launch
VERA
Product Launch
New Projects/Investments
- Vera Therapeutics submitted its Biologics License Application (BLA) for Atakicept in IgA nephropathy (iGAN) on November 7, following positive Phase 3 data and breakthrough designation, anticipating a PDUFA date in July and a launch with an autoinjector.
- Atakicept, a dual BAF-APRL inhibitor, has demonstrated two-year kidney function data by estimated GFR and a safety profile similar to placebo, targeting a US patient population of approximately 160,000 biopsy-confirmed cases.
- The company is well-capitalized with an estimated $400 million-$500 million ending the year and access to an additional $500 million, providing approximately $1 billion for the launch next year.
- Vera is also expanding its pipeline by studying Atakicept in other autoimmune kidney diseases and developing VT109, a new molecule for potential quarterly dosing.
Dec 3, 2025, 9:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more